See more : Fill Up Media S.A. (ALFUM.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Cogent Biosciences, Inc. (COGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cogent Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Spectur Limited (SP3.AX) Income Statement Analysis – Financial Results
- Basilea Pharmaceutica AG (BPMUF) Income Statement Analysis – Financial Results
- Virgin Money UK PLC (CYBBF) Income Statement Analysis – Financial Results
- NIC Autotec, Inc. (5742.T) Income Statement Analysis – Financial Results
- Tokens.com Corp. (SMURF) Income Statement Analysis – Financial Results
Cogent Biosciences, Inc. (COGT)
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Cost of Revenue | 3.59M | 5.88M | 147.00K | 25.74K | 43.71K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.59M | -5.88M | -147.00K | 7.85M | 22.46M | 9.73M | 8.36M | 6.36M | 2.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.67% | 99.81% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 170.17M | 121.63M | 55.91M | 72.65M | 43.71M | 38.29M | 29.83M | 21.99M | 6.85M |
| General & Administrative | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Other Expenses | 0.00 | 3.61M | 2.81M | -246.00K | 78.00K | 320.00K | 274.00K | 681.00K | 0.00 |
| Operating Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Cost & Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Interest Income | 13.08M | 3.99M | 467.00K | 144.00K | 267.00K | 1.15M | 386.00K | 265.00K | 0.00 |
| Interest Expense | 0.00 | 3.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.27M | 5.88M | 147.00K | 720.00K | 1.29M | 1.32M | 1.17M | 830.00K | 179.00K |
| EBITDA | -205.86M | -134.36M | -75.40M | -34.57M | -30.89M | -34.68M | -24.98M | -18.24M | -6.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,139.52% | -143.02% | -356.32% | -298.82% | -287.02% | -214.77% |
| Operating Income | -208.13M | -147.84M | -75.55M | -82.20M | -32.18M | -36.01M | -26.15M | -19.07M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,044.33% | -143.02% | -369.89% | -312.82% | -300.08% | -220.76% |
| Total Other Income/Expenses | 15.72M | 7.60M | 3.28M | 7.39M | 345.00K | 1.47M | 660.00K | 946.00K | 0.00 |
| Income Before Tax | -192.41M | -140.24M | -72.27M | -74.81M | -31.83M | -34.53M | -25.49M | -18.12M | -6.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -950.43% | -141.49% | -354.76% | -304.93% | -285.19% | -220.76% |
| Income Tax Expense | 0.00 | -7.60M | -467.00K | -8.36M | -1.56M | 1.47M | -386.00K | -265.00K | 0.00 |
| Net Income | -192.41M | -132.64M | -71.81M | -66.45M | -30.27M | -34.53M | -25.49M | -18.12M | -6.59M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -844.25% | -134.55% | -354.76% | -304.93% | -285.19% | -220.76% |
| EPS | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| EPS Diluted | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -2.45 | -0.89 |
| Weighted Avg Shares Out | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 5.86M | 5.86M |
| Weighted Avg Shares Out (Dil) | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 7.40M | 7.40M |
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data
Today, investors in Cogent Biosciences and COGT stock have some promising clinical trial results to look at, as this stock soars. The post Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data appeared first on InvestorPlace.
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
All patients treated with bezuclastinib achieved ≥ 50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
– Event to review initial clinical data from APEX, a Phase 2 trial with bezuclastinib in Advanced Systemic Mastocytosis presented at European Hematology Association (EHA) Congress – Event to review initial clinical data from APEX, a Phase 2 trial with...
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM)
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the LifeSci...
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results
APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients
Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming poster presentations at the...
Source: https://incomestatements.info
Category: Stock Reports